PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020
May 13 2020 - 5:05PM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced the
publication of its abstract on preclinical studies of PDS0102 at
the American Society of Clinical Oncology (ASCO) Virtual Scientific
Program being held May 29-31, 2020. The abstract confirms the
ability of the Versamune® platform to induce powerful killer T-cell
responses across tumor types.
Versamune® is a proprietary T-cell activating
platform technology designed to train the immune system to detect
and attack cancer cells. The published data demonstrate that
Versamune®, when combined with the proprietary T-cell receptor
gamma alternate reading frame protein (TARP), has the ability to
activate a powerful killer T-cell response which specifically
recognizes and attacks TARP-expressing cancer cells. PDS0102
is being developed to treat prostate and breast cancers, the
majority of which express the TARP protein. The results of this
study mirror the anti-HPV responses observed with the company’s
lead program, PDS0101 which is entering Phase 2 for HPV-associated
cancers.
“These data being presented at ASCO are
significant for our oncology portfolio and highlight the
versatility of our Versamune® platform in immuno-oncology,”
commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech.
“Our ongoing studies continue to demonstrate the ability of our
Versamune® platform to induce higher levels of potent,
cancer-attacking T-cells in vivo compared to other immunotherapy
technologies.”
Abstract e15211: “R-DOTAP (Versamune®): A Novel
Enantiospecific Cationic Lipid Nanoparticle That Induces CD4 and
CD8 Cellular Immune Responses to Whole Protein and Tumor-Specific
Peptide Antigens” is available on the ASCO meeting website at
abstracts.asco.org.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy
company with a growing pipeline of cancer immunotherapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology platform. Versamune®
effectively delivers disease-specific proteins for in vivo uptake
and processing by the immune system, while also activating the
critical type 1 interferon immunological pathway. This
results in the production of potent disease-specific killer T-cells
as well as neutralizing antibodies. PDS Biotech has engineered
multiple therapies, based on combinations of Versamune® and
disease-specific antigens, designed to train the immune system to
better recognize disease cells and effectively attack and destroy
them. To learn more, please visit www.pdsbiotech.com or follow us
on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines
the Versamune® platform with tumor-associated HPV-proteins in order
to induce a powerful T-cell attack against HPV-containing cancer
cells. PDS0101 is being developed to treat HPV-associated
cancers such as head and neck, anal and cervical cancers. In
partnership with Merck, PDS Biotech is advancing a combination of
PDS0101 and KEYTRUDA® to a Phase 2 study in first line treatment of
recurrent or metastatic head and neck cancer in which Keytruda has
been approved as the standard of care. In partnership with
the National Cancer Institute (NCI), PDS Biotech is advancing a
combination of PDS0101 with the promising clinical stage
immunotherapies M7824 and NHS-IL12 into a Phase 2 clinical study in
advanced HPV-associated cancers. A third phase 2 study in
advanced localized cervical cancer combines PDS0101 with standard
of care chemoradiotherapy.
About PDS0102
PDS0102 combines the utility of the Versamune®
platform with the proprietary T-cell receptor gamma alternate
reading frame protein (TARP), a tumor antigen identified by the
National Cancer Institute (NCI) which is strongly associated with
prostate and breast cancers. Approximately 450,000 patients are
projected to be diagnosed with prostate or breast cancer this year,
most of which are associated with TARP.
Forward Looking Statements
This communication contains forward-looking
statements (including within the meaning of Section 21E of the
United States Securities Exchange Act of 1934, as amended, and
Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”)
and other matters. These statements may discuss goals, intentions
and expectations as to future plans, trends, events, results of
operations or financial condition, or otherwise, based on current
beliefs of the Company’s management, as well as assumptions made
by, and information currently available to, management.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,”
“would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” and
other similar expressions among others. Statements that are not
historical facts are forward-looking statements. Forward-looking
statements are based on current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the Company’s ability to
protect its intellectual property rights; the Company’s anticipated
capital requirements, including the Company’s anticipated cash
runway and the Company’s current expectations regarding its plans
for future equity financings; the timing for the Company or its
partners to initiate the planned clinical trials for its lead
assets, PDS0101; the Company’s interpretation of the results of its
Phase 1 trial for PDS0101 and whether such results are sufficient
to support additional trials or the future success of such
trials; the successful implementation of the Company’s
research and development programs and collaborations, including any
collaboration studies concerning PDS0101 and the Company’s
interpretation of the results and findings of such programs and
collaborations and whether such results are sufficient to support
the future success of the Company’s product candidates; the
acceptance by the market of the Company’s product candidates, if
approved; the timing of and the Company’s ability to obtain
and maintain U.S. Food and Drug Administration or other
regulatory authority approval of, or other action with respect to,
the Company’s product candidates; and other factors, including
legislative, regulatory, political and economic
developments not within the Company’s control, including
unforeseen circumstances or other disruptions to normal business
operations arising from or related to COVID-19. The foregoing
review of important factors that could cause actual events to
differ from expectations should not be construed as exhaustive and
should be read in conjunction with statements that are included
herein and elsewhere, including the risk factors included in the
Company’s annual and periodic reports filed with the SEC. The
forward-looking statements are made only as of the date of this
press release and, except as required by applicable law, the
Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Tram Bui / Alexander LoboThe Ruth GroupPhone: +1
(646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com /
alobo@theruthgroup.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024